Cigna Corporation
NYSE:CIMedical - Healthcare Plans
-$4.44 today
- Market cap
- $75.20B
- Beta
- 0.30
- P/E (TTM)
- 11.7
- EPS (TTM)
- $23.95
- Dividend yield
- 2.19%
Volume 2.49M
Average 1.61M
CI Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Cigna CorporationNYSE: CI
Cost of Revenue · Q3 FY2026 · quarter ended Sep 2026
Cost of revenue growth accelerates
Q3 FY2026 cost of revenue of $71.29B rose 11.7% year over year, ahead of the +6.5% change in trailing-twelve-month cost of revenue. Sequentially, it rose 25.7% from the prior quarter. Over 3 fiscal years it compounded at +16.6% a year.
Context
- Cost of revenue amounted to 90.5% of revenue in FY2025, up 1.1 pp from a year earlier.
- Cost of revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +11.7% holds above the trailing-twelve-month pace of +6.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 248.97B USD
- Year-over-year change
- +12.6%
- 4-year CAGR
- +13.3%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 248.97B | +12.6% |
| FY2024 | 2024-12-31 | 221.16B | +30.0% |
| FY2023 | 2023-12-31 | 170.09B | +8.3% |
| FY2022 | 2022-12-31 | 157.02B | +3.9% |
| FY2021 | 2021-12-31 | 151.12B | — |
Cost of Revenue vs competitors
How CI compares with its peers on the latest reported figures
- CI's LTM Sep 2026 cost of revenue of $256.93B is the 3rd highest of the 9 companies compared; the peer median is $131.09B.
- Its year-over-year change of +6.5% is the 5th highest of 9, against a peer median of +3.5%.
- Cost of revenue amounts to 89.7% of revenue for CI, versus a peer median of 84.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $356.34B | +6.9% | +9.0% | 85.8% | |
| LTM Sep 2026 | $347.08B | -0.7% | +14.2% | 77.2% | |
| LTM Sep 2026 | $256.93B | +6.5% | +16.6% | 89.7% | |
| LTM Jun 2026 | $162.49B | +0.1% | +10.2% | 83.9% | |
| LTM Sep 2026 | $134.12B | +24.8% | +13.5% | 87.0% | |
| LTM Sep 2026 | $128.05B | -10.9% | +8.3% | 63.4% | |
| LTM Sep 2026 | $40.11B | +0.1% | +13.8% | 91.9% | |
| LTM Jun 2026 | $8.44B | +22.7% | — | 55.1% | |
| LTM Mar 2026 | $3.73B | +40.5% | +40.4% | 87.6% | |
| Peer median (excluding CI) | $131.09B | +3.5% | +13.5% | 84.9% | |
Competitors are the stored peer set for CI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 174.07B | 180.52B | 195.27B | 247.12B | 274.95B |
| Cost of Revenue | 151.12B | 157.02B | 170.09B | 221.16B | 248.97B |
| Gross Profit | 22.95B | 23.5B | 25.18B | 25.96B | 25.99B |
| Gross Margin | 13.2% | 13.0% | 12.9% | 10.5% | 9.5% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 12.79B | 13.05B | 14.32B | 14.57B | 14B |
| Operating Expenses | 15.01B | 15.05B | 16.64B | 16.55B | 16.86B |
| Depreciation & Amortization | 2.92B | 2.94B | 3.04B | 2.78B | 2.78B |
| EBITDA | 11.09B | 11.52B | 12.07B | 12.47B | 11.75B |
| EBITDA Margin | 6.4% | 6.4% | 6.2% | 5.0% | 4.3% |
| Operating Income | 7.94B | 8.45B | 8.54B | 9.42B | 9.13B |
| Operating Margin | 4.6% | 4.7% | 4.4% | 3.8% | 3.3% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 1.21B | 1.23B | 1.45B | 1.44B | 1.38B |
| Other Income / Expenses | (1.15B) | (53M) | (3.02B) | (4.15B) | (1.54B) |
| Income Before Tax | 6.79B | 8.4B | 5.51B | 5.27B | 7.59B |
| Pre-Tax Margin | 3.9% | 4.7% | 2.8% | 2.1% | 2.8% |
| Income Tax Expense | 1.37B | 1.62B | 141M | 1.49B | 1.35B |
| Net Income | 5.37B | 6.7B | 5.16B | 3.43B | 5.96B |
| Net Margin | 3.1% | 3.7% | 2.6% | 1.4% | 2.2% |
| EPS (Basic) | 15.89 | 21.66 | 17.57 | 12.25 | 22.30 |
| EPS (Diluted) | 15.75 | 21.41 | 17.39 | 12.12 | 22.17 |
| Weighted Avg Shares | 337.96M | 313.07M | 296.88M | 280.29M | 265.95M |
| Weighted Avg Shares (Diluted) | 340.97M | 313.07M | 296.88M | 283.22M | 265.95M |
Cigna Corporation
NYSE:CI
Intrinsic Alpha fair value
Locked
Current Price
$285.37
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.